Adverse changes in the environment of cells induce the expression of heat shock proteins such as the 7OkDa heat shock protein hsp70 (Lindquist and Craig, 1988) . This response takes place when cells are subjected to a wide variety of stressors, e.g. environmental assaults or states of disease (Parsell and Lindquist, 1994) . The understanding of stress response is still incomplete but the promise of its clinical application and its role in cancer development is under intense investigation. Hsp7O overexpression has been reported to induce cytoprotection under a broad variety of adverse conditions in vivo and in vitro (reviewed in Parsell and Lindquist, 1994) . Antineoplastic drugs act via a variety of mechanisms, including inhibition of topoisomerases or modification of proteins and DNA. It has been reported that the overexpression of certain heat shock proteins confers resistance to at least some antineoplastic drugs (Osterreich et al., 1993; Karlseder et al., 1996) , therefore heat shock protein overexpression in malignant cells could adversely influence the efficacy of antineoplastic therapy (Ciocca et al., 1993; Fuqua et al., 1994a,b) . In the present study we used two new drugs, topotecan [(S)-9-dimethylaminomethyl-10-hydroxycampothecin hydrochloride; SK&F 104864-A, NSC 609699] and gemcitabine, dFdC, (2',2'-difluorodeoxycytidine). Topotecan is a water-soluble semisynthetic analogue of the alkaloid campothecin, which is a potent topoisomerase I inhibitor. Gemcitabine is a deoxycytidine antimetabolite, presumably exerting its antineoplastic activity by the incorporation of dFdC into the genome.
It was the purpose of this study to elucidate the influence of hsp70 overexpression on the cytotoxic effects of topotecan and gemcitabine using a fibrosarcoma WEHI-S cell line, stably transfected to constitutively overexpress the human hsp70 (Hunt and Morimoto, 1985) cDNA (WN113) and a corresponding control transfected with an empty plasmid (Jaiattela et al., 1992) .
Hsp7O overexpression has been reported in several human malignancies. In contrast to the artificial overexpression of hsp70 by the heterologous SV40 promoter in WN113 cells these malignant cells express hsp70 obviously by constitutive activation of their genuine hsp70 promoter. Given the desensitising activity of hsp70 with respect to antineoplastic therapy we sought to inactivate the transcriptional activity of that promoter, thus sensitising these cells to topotecan and gemcitabine. Inducible heat shock proteins, e.g. hsp90, hsp70 or hsp27, are transcriptionally regulated by heat shock transcription factors (HSFs) (Larson et al., 1988) . HSF is expressed constitutively in an inactive form and posttranslationally activated by a variety of events. The transcriptionally active HSF molecule migrates into the nucleus and binds to a promoter element (HSE), which most stress-inducible promoters of heat shock protein genes have in common. Upon HSF binding to HSE the promoter is transcriptionally active and the heat shock proteins controlled by this mechanism are expressed (for review see Morimoto et al., 1994) . Cells constitutively bearing an activated HSF consequently not only express hsp27 but also other protective heat shock proteins, e.g. hsp90 or hsp27, all of which are regulated by this factor (Parsell and Lindquist, 1994) . In order to sensitise hsp-overexpressing tumour cells quercetin (3, 3', 4', 5, 7-pentahydroxyflavone), a bioflavonoid, which is found as a glycoside in citrus fruits, is a promising candidate molecule, as it has been reported to suppress the stress response in heat-shocked cells (Nagai et al., 1995; Lee et al., 1994) . Therefore, we applied quercetin as a sensitiser molecule to suppress hsp70 overexpression. To test the sensitising efficiency of quercetin in vitro, we used HaCaT cells (Boukamp et al., 1990; Breitkreutz et al., 1991) , which naturally show constitutive overexpression of hsp70.
Materials and methods Cell culture
To study the efficacy of high expression levels of hsp70 on the sensitivity to anti-cancer drugs an isogenic set of stably transfected murine fibrosarcoma cell lines, kindly donated by Dr Marja Jaiittela, Danish Cancer Society Research Centre, Copenhagen, Denmark, was used (Jaiittela et al., 1992) . WN1 13 cells were generated by transfection of WEHI-S cells with a SV40-driven human hsp7O cDNA expression vector. WN1Ox cells represent a mixed culture of WEHI-S clones stably transfected with an empty control plasmid. Both WNl 13 and WN1Ox cells were co-transfected with a vector carrying the neomycin resistance gene for adequate selection by use of G418. Cells were propagated in RPMI-1640 culture medium, containing 10% fetal bovine serum, 2 mM glutamine, 1% antibiotic/antimycotic supplements and 200 ,ug ml-' G418 (all Gibco, UK). Monolayer cells were routinely passaged at subconfluence by 0.25% trypsin-EDTA. To avoid an induction of the heat shock response media and phosphate buffered saline (PBS) were equilibrated at 37°C before use.
The human skin keratinocyte cell line (HaCaT) was provided by Professor Dr N E Fusenig, Institute of Biochemistry, German Cancer Research Centre, Heidelberg, Germany. HaCaT cells served as an example for tumour cells that show enhanced hsp7o expression levels. They were routinely grown in RPMI-1640 medium, containing 10% fetal bovine serum, 2 mM glutamine, 1% antibiotic/antimycotic supplement.
Chemotherapeutic drugs and cytotoxicity assay Topotecan [(S)-9-dimethylaminomethyl-10-hydroxycampothecin hydrochloride; SK&F 104864-A, NSC 609699] was kindly provided by SmithKline Beecham Pharma, UK. This drug was shown to be active in a lactone form only (Burke and Mi, 1994) . The equilibrium of lactone and carboxylate form is dependent on pH, protein concentration and other factors. The actual concentration of lactone for this in vitro model was not determined, therefore, the concentrations used in our in vitro conditions, which were stable whithin the experiments, cannot be compared with those applied in vivo. Gemcitabine (2',2'-difluorodeoxycytidine) was a gift from Eli Lilly, Austria. The antineoplastic drugs were dissolved in dimethyl sulphoxide (DMSO) and stored as recommended. Growth inhibition was determined essentially as described previously (Simon et al., 1995) . Briefly, 100 ,l of cell suspension was seeded at a density of 5 x 104 cells ml-' in 96-well plates in RPMI-1640 culture medium, containing 10% fetal bovine serum and 200 Mg ml-' G418 (all from Gibco). After 16 h medium was replaced and cells were incubated with the antineoplastic drugs at concentrations as indicated. A negative control sample was prepared by complete lysis of cells by addition of 5% of sodium-Nlauroylsarcosin (Sigma, St Louis, MO, USA). As the doubling rates of WN1Ox and WN1 13 cells were found to be essentially the same (data not shown) actual cell numbers were not determined at the time point of drug addition. Cells were exposed to the antineoplastic drugs for a period of 48 h at 37°C. To determine the metabolic activity 20 ,l of MTT solution (Sigma 1.5 mg ml-') dissolved in RPMI-1640 was added and incubated at 37°C for exactly 6 h. Then 100 Ml of lysis buffer [10% sodium dodecyl sulphate (SDS), 50% formamide adjusted to pH 4.7 with acetic acid] was added and incubated overnight at room temperature to lyse cells and solve the formazane precipitate. The clear solution was measured at 595 nm on a baseline of the completely lysed negative control extinction. The resulting percentage growth inhibition rates represent the metabolic activity (OD595) after a 48 h period of culture in continuous presence of the drugs. All experimental series were performed independently at least three times and minimally in triplicates.
Determination of the ability of cells to re-enter the cell cycle after drug withdrawal To determine the capability of cells to restart cell growth after withdrawal of the drugs two identical sets of 96-well plates were seeded and treated with the drugs as described. After a period of 24 h the metabolic activity was determined in the first set of 96-well plates whereas the second set was washed twice and grown for an additional 48 h. The metabolic activity was then also determined in the second set. The capability of cells to restart cell growth was expressed as the percentage increase (or decrease) of OD595 of the second set containing recovered cells compared with the OD595 measured at the time point of removal of the drug (set to 100%). A change in metabolic activity exceeding 100% indicates that cells were able to re-enter the cell cycle after withdrawal of the drug, whereas values below 100% demonstrated that cells were still arrested or had died.
Quercetin treatment The sensitising effect of quercetin was assayed in HaCaT cells, which show constitutive hsp70 expression. A quercetin stock solution was prepared in DMSO. Sterile filtered aliquots were kept at -20°C. The toxicity of quercetin was determined by an MTT assay as described for the drugs after continuous treatment for 48 h. As high doses of quercetin interfered with the MTT colour reaction, cells were washed before the addition of the MTT assay medium. In order to inactivate the constitutively active heat shock transcription factor in HaCaT cells they were grown for 36 h in the presence of quercetin at concentrations as indicated. After the medium containing the same quercetin concentration was changed the drugs were added followed by an incubation for 48 h. Then a growth inhibition assay was performed as described. The cell survival is expressed as per cent OD595 of treated cells vs non-treated cells normalised to the completely lysed negative control.
Western blot analysis. HaCaT cells were propagated as mentioned, supplemented with 10% fetal calf serum (FCS) in the presence of indicated concentrations of quercetin for 36 h. Cells were detatched from the culture plates by use of a rubber policeman. Cytosolic protein lysates were essentially prepared as described previously (Simon et al., 1994) . Briefly, cells were allowed to swell in hypotonic buffer [10 mM HEPES, pH 7.8, 0.1 mM ethylenediamine tetraacetic acid (EDTA), 10 mM KCl, potassium chloride 1 mM dithiothreitol (DTT), phenylmethylsulphonyl fluoride (PMSF)] for 15 min on ice. Equal amounts of protein as determined using the ProteinAssay (Biorad, Vienna, Austria) were subjected to denaturing SDS/ polyacrylamide electrophoresis and subsequently blotted onto nitrocellulose filters. Hsp7O was detected by use of an antibody specific for the stress-inducible hsp7o (anti-hsp72, SPA810, StressGen Victoria, BC, Canada) and an alkaline phosphatase coupled anti-mouse IgG antibody (Boehringer Mannheim, Mannheim, Germany).
Results
Hsp7O overexpression is sufficient to render cells resistant to topotecan and gemcitabine The cytotoxic activity of topotecan and gemcitabine for control WN1Ox and WNI113 cells was determined. WN1 13 cells are stably transfected to express high levels of hsp7o using the constitutive viral SV40 promoter. Figure 1 demonstrates the impact of hsp7o on the drug sensitivity. Whereas the protective effect against gemcitabine was moderate with a factor of 2-3, cells overexpressing hsp7o could bear an almost 10-fold topotecan dosage. Figure 5 quercetin pretreatment markedly increased the sensitivity of HaCaT cells to both drugs in a concentration-dependent manner.
Discussion
The development of resistance of tumour cells to anti-cancer drugs is one of the critical issues for successful chemotherapy. Stress-inducible heat shock proteins render cells resistant to a variety of antineoplastic drugs (Hahn and Li, 1990) . In the present study high levels of hsp7O induced by an expression vector carrying the hsp70 cDNA transcribed from the strong and constitutive SV40 promoter were sufficient to provide protection against topotecan and gemcitabine in the isogenic cell system of WNI13 and WNlOx cells. In order to draw clinically relevant conclusions from our in vitro system antineoplastic drugs were applied in concentrations near the 176 maximum tolerable dose. From our results we conclude that the antineoplastic activity of topotecan and gemcitabine is reduced in hsp70-overexpressing cells. An hsp70-mediated elevation of resistance by a factor of 2 or 3. as demonstrated in our study. could be detrimental for the success of chemotherapy. Furthermore, it could be speculated that the protective action of hsp7O exhibits a certain drug specificity. The protective effect of hsp70 overexpression against cytotoxicity was more pronounced for topotecan than for gemcitabine. This could be explained by different mechanisms by which these drugs exert toxicity (Figure 1 ). A suggested model on the mechanism of hsp7O-mediated cytoprotection is based on the ability of hsp7O to bind misfolded or aggregated proteins. The energy-dependent dissociation of the substrate peptide-hsp70 complex is thought to enable these peptides to acquire a proper folding (Gething and Sambrook. 1992) . Hsp7O in Escherichia coli was able to restore enzyme activity of damaged proteins (Skowyra et al.. 1990; Schroder et al.. 1993 ). However, a detailed mechanism of such a versatile cross-protection as provided by overexpression of hsp7O and other heat shock proteins with regard to the drugs used is not known. We found that hsp7O-overexpressing cells not only survive enhanced doses of topotecan or gemcitabine but were also able to start proliferation after application of antineoplastic drug doses at which control cells remained arrested or died. It was reported that hsp7O overexpression conferred resistance to ultraviolet light or reactive oxygen intermediates (Simon et al.. 1995) but on the other hand enhanced the number of surviving mutants as a result of the DNA-damaging treatment (Suzuki and Watanabe. 1994) . Accordingly. the pronounced capability to restart cell growth after drug treatment could lead to the enhanced outgrowth of mutated cells when hsp70 is overexpressed. Hsp7O-protected tumour cells bear a higher risk of developing viable mutants, which could give rise to secondary tumours after treatment with a genotoxic chemotherapy. High constitutive expression of hsp70 was found in a variety of tumours. in particular in breast cancer, where hsp70 is regarded as an adverse prognostic marker (Fuqua et al.. 1994b : Ciocca et al.. 1993 Elledge et al.. 1994) . Topoisomerase I inhibitors such as topotecan show significant activity against a broad range of tumours and are not substrates for the multidrug resistance P-1 70 glycoprotein and the multidrug resistance-associated proteins (Sinha. 1994). Gemcitabine. a new cytidine analogue. has shown impressive activity as a single agent against several solid malignancies. demonstrating that in solid tumours deoxycytidine kinase can be an important target for the activation of antimetabolites (Ruiz van Haperen and Peters. 1994 ). In addition. gemcitabine has also been shown to be active against multidrug-resistant human tumours xenografted into nude mice (Fujita et al.. 1994a.b) . The capability of hsp7O-overexpressing tumour cells to regrow after treatment with antineoplastic drugs consequently could be of considerable importance in the clinical setting.
After demonstrating that hsp7O overexpression alone is sufficient to desensitise cells to the antineoplastic activity of topotecan and gemcitabine it was our aim to evaluate how tumour cells, which naturally overexpress hsp7O. could be sensitised to a chemotherapy with topotecan and gemcitabine. Such tumour cells are reported; however. the reason for the high hsp7O expression in these cells is unknown. To gain a model for a tumour cell that constitutively expresses hsp7O by use of its genuine hsp7O promoter we used the HaCaT cell line, which we found to be suitable for this purpose. Inducible heat shock proteins. e.g. hsp9O. hsp7O or hsp27. are transcriptionally regulated by heat shock transcription factors (HSFs) (Larson et al.. 1988 ). Cells having constitutively activated HSF consequently not only express hsp7O but also other protective heat shock proteins. e.g. hsp9O or hsp27. all of which are regulated by this factor (Parsell and Lindquist. 1994) . The combined expression of several protective heat shock proteins therefore might account for the decreased sensitivity of HaCaT cells to the drugs when compared with WNl 13 cells. One possible access to lower the overall level of heat shock proteins is to specifically block the transactivating potential of HSF. Such HSF-inhibiting properties were found for the flavonoid quercetin (Hosokawa et al.. 1992) . Pretreatment of HaCaT cells with different dosages of quercetin dramatically reduced the hsp7O level (Figure 4 ). dosages which did not affect the growth properties of the cells (Figure 3) . Continuous long-term culture in the presence of less than 1 pm quercetin was effective in significantly reducing hsp7O (data not shown). Quercetin obviously is an effective tool for reducing genuine hsp7O levels. It is likely that other protective heat shock proteins that are under transcriptional control of HSF are also suppressed by quercetin treatment. As expected quercetin depleted HaCaT cells from protective hsp7O (Figure 4 ) and consequently these cells showed a profound quercetin dosagedependent sensitisation to topotecan as well as to gemcitabine. In summary, we conclude that quercetin could be considered as a chemosensitiser in combination with conventional chemotherapy.
